Cargando…
Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing
Fibrotic diseases contribute to 45% of deaths in the industrialized world, and therefore a better understanding of the pathophysiological mechanisms underlying tissue fibrosis is sorely needed. We aimed to identify novel modifiers of tissue fibrosis expressed by myofibroblasts and their progenitors...
Autores principales: | Vollmann, Elisabeth H., Cao, Lizhi, Amatucci, Aldo, Reynolds, Taylor, Hamann, Stefan, Dalkilic-Liddle, Isin, Cameron, Thomas O., Hossbach, Markus, Kauffman, Kevin J., Mir, Faryal F., Anderson, Daniel G., Novobrantseva, Tatiana, Koteliansky, Victor, Kisseleva, Tatiana, Brenner, David, Duffield, Jeremy, Burkly, Linda C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424569/ https://www.ncbi.nlm.nih.gov/pubmed/28624207 http://dx.doi.org/10.1016/j.omtn.2017.04.014 |
Ejemplares similares
-
Therapeutic siRNA silencing in inflammatory monocytes
por: Leuschner, Florian, et al.
Publicado: (2011) -
siRNA and the lung: research tool or therapeutic drug?
por: de Fougerolles, Antonin, et al.
Publicado: (2008) -
Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells
por: Basha, Genc, et al.
Publicado: (2011) -
Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside
por: Zatsepin, Timofei S, et al.
Publicado: (2016) -
Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8(+) T Cell-mediated Hepatic Antiviral Immunity
por: Dolina, Joseph S, et al.
Publicado: (2013)